Inflated random effects showed by VPC
Dear all,
I wonder what might cause a pharmacokinetic model to have inflated variability.
For my model, the GOF plots look reasonably good--meaning that the fixed
effects are OK. However the prediction corrected VPC implemented by PsN
indicated severely overestimated variability regardless of whether I stratify
them into different dose groups or analysis them altogether. I have tried all
my candidate models, all of them have the observed 95th and 5th percentile way
off from the simulated confidence bands, and for some of them, the observation
points don't even go into the upper and lower confidence interval bands.
I checked my eta plots, and I think although they don't look perfectly normal,
they still looks reasonably symmetrical with a bell shape. Eta on V seems to be
a little skewed to the right. I don't have much experience on PopPK so I might
be wrong.
I think there might three possibilities causing this problem.
One is that, the true distribution of etas is not normally distributed but more
like uniformly distributed (or skewed). The estimation step have no problem of
identifying the right mean and variance for parameters even the true underlying
distribution is not normal distribution. But when it comes to simulation, the
simulated parameters are draw from the normal distribution with the estimated
mean and variance. That discrepancy might cause inflated variability in
simulated parameters and therefore inflated variability in simulated
observations.
The other is that there are a few subjects having very large eta compared with
other subjects, therefore inflated the estimated omega.
Also all my subjects are dosed based on their weight, height, gender and age to
achieve a target drug concentration level. They might do a very good job making
the concentrations to reach the target level so all of my observations lies in
the middle of the prediction corrected VPC plots. I think this is the least
likely possibility since I have already taken covariate effects into
consideration in some of my models..
I am not sure I am thinking it right. Please correct me if I am wrong. Does
anyone have any thoughts into this? Has anyone encountered similar things
before? I truly appreciate any comments or suggestions.
Yu
Graduate student in Clinical Pharmaceutical Science
University of Iowa